Results 271 to 280 of about 1,885,895 (335)

The effect of cytoreductive nephrectomy on survival in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors. [PDF]

North Clin Istanb
Bilgetekin I, Ozturk E, Karacin C, Basal FB, Akdagcik Z, Oksuzoglu B.   +5 more
europepmc   +1 more source

Bibliometric analysis and recent trends on tyrosine kinase inhibitors in leukemia. [PDF]

Discov Oncol
Cheng J, Fang Y, Dong J, Zhang X, Yuan Y, Dang X.   +5 more
europepmc   +1 more source

Risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitors. [PDF]

Eye (Lond)
Mohan N, Srivastava SK, Duphare C, Gilligan TD, Ali MY, Ornstein MC, Sobecks R, Shepard D, Sharma S.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

.EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.

Pharmacological Research, 2021
With the development of precision medicine, molecular targeted therapy has been widely used in the field of cancer, especially in non-small-cell lung cancer (NSCLC).
Rui-Fang Dong, Miao-Lin Zhu, Ming-Ming Liu, Yi-ting Xu, Liu-Liu Yuan, Jing Bian, Yuan‐zheng Xia, Lingyi Kong   +7 more
semanticscholar   +1 more source

Tyrosine Kinase Inhibitors

Current Cancer Drug Targets, 2010
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinases signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast ...
NATOLI, Clara, Perrucci Bruno, Perrotti Francesca, Falchi Lorenzo, IACOBELLI, Stefano, Consorzio Interuniversitario Nazionale per Bio Oncologia   +5 more
openaire   +3 more sources

Inhibitors of tyrosine kinase

Current Opinion in Oncology, 1997
This review covers the literature on significant studies of small molecule inhibitors of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), Flk-1, and src family tyrosine kinases from 1996 through mid-1997. During this period, there has been substantial progress in the
W D, Klohs, D W, Fry, A J, Kraker
openaire   +2 more sources

Molecular targets of tyrosine kinase inhibitors in thyroid cancer.

Seminars in Cancer Biology, 2020
Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with medullary TC (MTC) and differentiated TC (DTC).
P. Fallahi, S. Ferrari, M. Galdiero, G. Varricchi, G. Elia, F. Ragusa, S. Paparo, S. Benvenga, A. Antonelli   +8 more
semanticscholar   +1 more source

Efficacy of Tyrosine Kinase Inhibitors in Ph-like Acute Lymphoblastic Leukemia harboring ABL-class Rearrangements.

Blood, 2019
Tanasi et al present a prospective strategy for identifying patients with Philadelphia-like acute lymphoblastic leukemia, demonstrating the efficacy of early introduction of tyrosine kinase inhibitors in improving outcomes.
Ilaria Tanasi, I. Ba, N. Sirvent, T. Braun, W. Cuccuini, P. Ballerini, Nicolas Duployez, A. Tanguy‐Schmidt, J. Tamburini, S. Maury, E. Doré, C. Himberlin, C. Duclos, P. Chevallier, P. Rousselot, M. Bonifacio, H. Cavé, A. Baruchel, H. Dombret, J. Soulier, J. Landman-Parker, N. Boissel, E. Clappier   +22 more
semanticscholar   +1 more source